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Systemic autoimmune diseases commonly affect women during childbearing years. With advances in therapies for these diseases, many patients have sustained periods of disease quies cence, less progressive disability and may be more likely to consider childbearing and child rearing. When treating women of childbearing age with chronic medications, it is imperative that the potential effects of medication use on the developing fetus are considered, whether a future pregnancy is planned or an unanticipated pregnancy is discovered. The goals of treatment are to control maternal disease activity while simultaneously maximizing the potential for a safe and successful outcome for the fetus. Since randomized controlled trials of medications for pregnant or lactating women are not rou tinely performed, most of the data available are based on animal data, individual case reports and observational cohorts. With extremely few exceptions, no medications are deemed to be without any risks to the expectant mother or developing fetus. However, some medications may elicit fewer safety concerns than others and may be considered safer alternatives for the successful control of maternal disease. Greater knowledge of the risks and benefits of commonly used immunosuppressive drugs during preg nancy and lactation will enable improved pre conceptional counseling for women who desire a future pregnancy and improved counsel ing and manage ment of patients who inadvertently become pregnant while undergoing disease modifying therapy and wish to continue the pregnancy, as well as improving the management of patients with increased disease activity during an established pregnancy.
The US FDA has a classification system for pregnancy risk that ranges from A (studies demonstrating safety in animals and humans) to X (absolutely contraindicated in preg nancy) [101] . Drugs are given a classification at the time of approval, often based primarily on animal studies, and are generally not updated as new evidence becomes available. Therefore, the current classification system may not be the most accurate resource for managing medica tion exposures during pregnancy. A narrative summary of potential risks and benefits of the commonly used medications for the treatment of autoimmune diseases is presented below.
NSAIDs
It is unclear if NSAIDs have an effect on fertil ity. Both cyclooxygenase (COX)1 and COX2 have been demonstrated to be involved in ovula tion and implantation in animal studies [1] . In humans, there have only been small case report series describing infertility caused by NSAID use owing to inhibition or delay in the luteinized follicle [2, 3] . Other reports have suggested that NSAID use may increase the risk of miscarriage. In a prospective cohort study by Li et al. with 1055 pregnant women in the Kaiser Permanente population, use of NSAIDs or aspirin around the time of conception and/or during pregnancy increased the risk of miscarriage [4] . The haz ard ratio for NSAID use versus no NSAID use in this study was 1.8 (95% CI: 1.0-3.2) but increased to 5.6 (95% CI: 2.3-13.7) if taken during the week of conception and increased to 8.1 (95% CI: 2.8-23.4) if taken for more than 1 week. Paracetamol use did not affect risk. By contrast, another study examined pregnancy outcomes among aspirin users compared with nonusers and did not find a difference in miscar riage between the two groups (risk ratio: 0.92; 95% CI: 0.71-119). Based on these data, it is suggested that patients should discontinue the use of NSAIDs or use them sparingly while try ing to conceive, especially if there is difficulty with conceiving.
The effect of NSAID use on the fetus is dependent upon the trimester. A number of cohort studies looking at the teratogenicity risk of NSAID use during the first trimester have not found an increased risk of congeni tal malform ations [5] . It should be noted that Immunosuppressive medications & lactation in women with autoimmune diseases -Review selective COX2 inhibitors were not studied and pregnancy outcomes have not been well observed. However, there is concern for adverse fetal outcomes with lateterm NSAID use, namely constriction and/or premature closure of the ductus arteriosus. Both COX1 and COX2 are expressed in the smooth muscle and endo thelial cells and when inhibited, constriction occurs. The majority of studies reviewing this have noted it as a lateterm manifestation occur ring primarily after the 27th week. Therefore, NSAIDs should be used sparingly during the first and second trimesters and stopped com pletely during the third trimester of pregnancy.
The NSAIDs that the American Academy of Pediatrics (AAP) consider to be compatible with breastfeeding include ibuprofen, indomethacin, diclofenac, naproxen, piroxicam, ketorolac and tolmetin [6] . These recommendations are based on observational studies looking at adverse effects on the infant and/or based on expert opinion. Owing to the fact that NSAIDs are weak acids, usually only a small amount will enter into breast milk, and this is often less than 5% of a therapeutic infant dose [7] . Ibuprofen has an especially low level in breast milk and a short halflife, and is therefore considered to be a reasonable choice as an analgesic for the lactating mother.
Corticosteroids
Corticosteroids vary structurally and will affect the mother and fetus differently. bmethasone and dexamethasone have fluorine at the 9a posi tion and are not well metabolized by the pla centa. They will cross the placenta and have direct effects on the fetus. However, most other cortico steroids are metabolized in the placenta by 11bhydroxysteroid dehydrogenase to inactiv ated forms, leaving less than 10% of the active drug to reach the fetus [8] . If the goal is to treat the mother, prednisone is the most ideal gluco corticoid since a very small amount of active drug will enter the fetal circulation. If the goal is to treat the fetus, bmethasone and dexa methasone are better options and are commonly used in women who are at risk for preterm delivery in order to reduce the risk for respiratory distress and cerebral hemorrhage in the preterm infant. Some recent reports suggest that bmethasone may be preferred to dexamethasone since it may offer bet ter longterm neurodevelopmental outcomes for the fetus. [9, 10] .
Corticosteroids carry a risk of elevated blood pressure, steroidinduced hyperglycemia and osteopenia. These risks are pertinent in a pregnant woman since pregnancy requires tight blood pressure control and may induce insulin resistance (and often frank gestational diabe tes), as well as osteopenia or osteoporosis. These issues can be exacerbated by steroids; therefore, proper monitoring and calcium and vitamin D supplementation should be employed.
Nonfluorinated corticosteroids do not appear to put the fetus at risk for congenital abnormali ties; however, there have been a few reports of an increased risk of cleft lip and/or palate, which are first trimester risks. A metaanalysis investigating birth defects after maternal exposure to cortico steroids reported a 3.3fold increase in the odds ratio of cleft lip and/or palate after first trimester exposure [11] . Subsequent studies have reported mixed results -some showing similar results and some showing no difference. However, if there is an increase risk, it should be noted that cleft pal ates occur at a rate of approximately one in 1000 individuals in the general population and, thus, the risk with steroid use would increase this to three in 1000. This small increase in risk should be weighed against the need to treat active dis ease in the mother. There have also been rare isolated reports of neonatal cataracts and adrenal suppression in infants after corticosteroid use, which may be dosedependent [5] .
The pharmacokinetics of prednisolone, the active form of prednisone, have been studied in breast milk [11, 12] . Levels measured in the milk are typically less than 0.1% of the total predniso lone dose ingested by the mother, which is less than 10% of the infant's endogenous cortisol production (when smalltomoderate doses are being used). Ost et al. evaluated a patient taking up to 80 mg of daily prednisolone and calcu lated that the prednisolone ingested from the milk would add, at most, 10% to the endogenous corticosteroid production of the infant, which may have little clinical significance [12] . Peak ste roid levels in breast milk occur approximately 2 h after a dose is taken and decline rapidly [11] . These smalltomoderate amounts of cortico steroids do not appear to have adverse effects on the developing infant; however, exposure may be minimized if nursing is performed 3-4 h after the dose is taken.
Hydroxychloroquine
Despite initial animal studies demonstrating toxic ity to retinal and auditory structures in ani mal teratogenicity studies of high doses of chloro quine [13] , data have accumulated in support of the safe use of hydroxychloroquine (HCQ; up to 400 mg daily) during human pregnancy [5] .
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There have been a number of observational studies and a recent metaanalysis demonstrat ing no increased risk of congenital abnormali ties or increased risk of miscarriage using the typically prescribed dose of 200-400 mg HCQ daily [14] [15] [16] . Clowse et al. not only reported the safety of HCQ, but also found that HCQ use was associated with decreased disease activity among lupus patients [17] . A single placebocon trolled, randomized, doubleblinded study has been performed to assess the role of HCQ dur ing pregnancy in lupus patients [18] . Again, the data demonstrated no congenital malformations associated with HCQ. All cases of disease flareup during pregnancy and preeclampsia were in the placebo group. HCQ crossed the placenta and the concentration in cord blood was approximately equal to maternal concentrations, but excretion into breast milk was very low (<0.2 mg/kg/day) and this level is not thought to be toxic [19] . If women remain concerned about antenatal expo sure to HCQ and wish to eliminate it from the maternal system prior to conception, it must be remembered that complete elimination may take 6 months. HCQ appears to be a safe option for conception, pregnancy and lactation.
Methotrexate
Methotrexate is an FDA category X medication that is contraindicated during pregnancy and is not considered safe in lactation. There are known risks of fetal abnormalities in humans asso ciated with methotrexate use. These risks have been observed in women being treated for cancer or when methotrexate was unsuccess fully used to terminate a pregnancy. However, there are also reports of fetal abnormalities when methotrexate has been used at doses prescribed in the rheumatology setting [20, 21] . In a recent systematic review, methotrexateexposed preg nancies using doses of 5-25 mg/week in the first trimester were analyzed. The number of meth otrexateexposed pregnancies was 101. There were 19 miscarriages (23% of pregnancies), 55 live births (66% of pregnancies) and five of the babies had neonatal malformations (5% of pregnancies) [22] . Methotrexate is the firstline DMARD and is the drug of choice, especially as initial therapy, for the treatment of rheumatoid arthritis (RA). Therefore, all women of child bearing potential should be strongly counseled and advised to use reliable forms of contracep tion while taking methotrexate. Furthermore, the patient and practitioner should have a discus sion regarding the use of alternative agents when initiating treatment, especially if pregnancy is desired in the near future or the practitioner feels that the patient's methods of contraception are unreliable. The same restrictions are also true for males. If a woman inadvertently becomes pregnant, she should discontinue the medica tion immediately, be counseled concerning the risks of congenital abnormalities and be referred immediately to a genetic counselor in order to discuss her options.
If a woman who is already being treated with methotrexate desires pregnancy, several issues need to be addressed during preconception counseling. One question that arises is for how long the drug should be discontinued before it is safe to conceive. Unfortunately, there is not a set guideline for this and, thus, practice is largely based on the known pharmaco kinetics of the drug. Dalrymple et al. recently studied the pharmaco kinetics of oral methotrexate in patients with RA [23] . The median times for metho trexate polyglutamate concentrations to become undetectable in red blood cells ranged from 4 to 10 weeks (also showing wide inter patient variability of elimination in adults with RA). Methotrexate is also widely distributed in tissues and can persist in the liver for up to 4 months after exposure [24] . Therefore, it is our practice to recommend discontinuing metho trexate at least 3 months prior to conception in order to allow adequate time for elimination of the drug. Methotrexate is also a derivative of aminopterin, which is a folate antagonist. Rheumatologists commonly prescribe folic acid supplementation during methotrexate therapy; however, folic acid supplementation should be continued during the preconception period, even after methotrexate is stopped, and should be continued throughout pregnancy. It is recommended that all pregnant women take at least 800 µg of folic acid daily in order to reduce the risk of neural tube defects. Closure of the neural tube occurs during the 5th week of pregnancy (3 weeks after conception), so early supplementation is essential.
Although the amount of methotrexate excreted in breast milk is very low, it is unknown how this may affect a young infant and, therefore, metho trexate is considered to be unsafe until more data become available.
Leflunomide
It is known that leflunomide causes fetal anom alies in animals, primarily CNS and skeletal anomalies. When leflunomide was given to rats at only 1% of the human dose, it resulted in fetal anomalies, decreased birth weight and increased Immunosuppressive medications & lactation in women with autoimmune diseases -Review mortality in the offspring after birth [25] . Based on available animal data, the FDA has categorized leflunomide as category X; this indicates that clear associations between the drug and fetal abnor malities have been identified and that the risks of use in pregnant humans outweigh any poten tial benefits. Managing elimination of lefluno mide in a woman who has become pregnant while taking leflunomide or desires pregnancy is neatly outlined by Brent in his article review ing the reproductive risks of lefluno mide, largely based on manufacturer and FDA recommenda tions [26] . The level that is believed to be safe in humans is 0.03 mg/l (i.e., ~10 halflives). If a woman treated with leflunomide wants to become pregnant, the medication should be stopped and cholestyramine should be administered in order to rapidly decrease the blood levels to this level. Cholestyramine of 8 g taken threetimes daily reduces the halflife of the active metabolite from up to 96 days to approximately 1 day. Therefore, a 10-11day regimen of 8 g cholestyramine three times daily is recommended. This approach is certainly conservative but was suggested by the FDA and is the manufacturer's recommenda tion. Plasma levels of the drug should be verified to be less than 0.03 mg/l by two separate tests performed 2 weeks apart. If levels still remain above 0.03 mg/l, the regimen should continue to be administered and women should use effective contraception until levels are below 0.03 mg/l. Based on the natural halflife of the drug (up to 96 days, as mentioned previously) it may take up to 2 years to reach plasma active metabolite levels of 0.03 mg/ml owing to individual varia tions; therefore, levels should be checked (and, if necessary, cholestyramine administered) in any patient who has been treated with leflunomide in the previous 2 years. This practice is also sup ported by a panel of 29 experts who participated in a consensus workshop on antirheumatic drugs during pregnancy and lactation [5] . Data from the Organization of Teratology Information Services (OTIS) Collaborative Research Group prospec tively evaluated 64 women with RA who were treated with leflunomide (95% of whom were treated with cholestyramine early in their preg nancy), 108 women with RA who were not treated with leflunomide and 78 healthy pregnant women. The rate of major structural defects in the exposed group was 5.4%, which was insigni ficant when compared with both comparison groups (4.2 and 4.2%, respectively; p = 0.13). Although the study group was small, these results are encouraging and suggest that these defects may be preventable with appropriate and early intervention [27] .
It is unknown how leflunomide exposure may affect a young infant and, therefore, lactation is considered to be unsafe in women treated with leflunomide; this is likely to remail the case until more data become available.
Sulfasalazine
Fertility in women does not appear to be affected by sulfasalazine use; however, it can lead to reduced fertility in men owing to oligospermia and reduced sperm motility. Fortunately, this is not an irreversible event; spermatogenesis should return to normal approximately 2 months after cessation of the drug. Men wishing to conceive a child with a partner should be counseled to discontinue the medication 3 months prior to conception [28] . It is also important to counsel men to explain that, although fertility may be reduced, the use of sulfasalazine is not consid ered to be an effective form of contraception. Abnormal or reduced spermatogenesis is due to the sulfasalazine metabolite, sulphapyridine.
In contrast to its effects on men, sulfasalazine is among the preferred DMARDs for pregnant women who require ongoing diseasemodifying therapy. Much of the data regarding pregnancy outcomes with sulfasalazine exposure are derived from the inflammatory bowel disease (IBD) litera ture. A recent metaanalysis of 2200 preg nant women with IBD (642 women received sulfasalazine or related agents) found no sta tistically significant differences for congenital anomalies (odds ratio: 1.16; 95% CI: 0.76-1.77) or other adverse pregnancy outcomes [29] . These data confirm several other reports of population based studies published over the past several decades [30, 31] . Congenital abnormalities dis cussed in isolated case reports have not been observed in systematic populationbased studies.
Two additional considerations are worth not ing. The first is the theoretical risk that sulfasala zine may cause folate deficiency since it inhibits dihydrofolate reductase and the cellular uptake of folate [32] . Pregnant women require at least 800 µg of folic acid replacement, which should be continued, and perhaps increased, during sulfasalazine use. Folic acid deficiency has been linked to neural tube defects, which can occur 5 weeks into pregnancy (or as early as 3 weeks after conception), so this should be part of the preconception planning discussions. The sec ond consideration is with regard to lateterm use. Sulfapyridine, a metabolite of sulfasalazine, can cross the placenta, displace bilirubin from albu min and possibly lead to neonatal jaundice [33] . Although there are no reports of this occurring
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after in utero exposure to sulfasalazine, one may consider discontinuing sulfasalazine use dur ing lactation in a preterm or jaundiced baby for 1-2 months.
Except in the setting of prematurity, hyper bilirubinemia or other acute stresses, sulfa salazine is considered safe during lactation. Sulphapyridine levels in breast milk were found to be approximately 30-60% of those in the mother's serum, but should not pose a risk to a healthy fullterm infant [34] .
Anti-TNF agents
There are few data regarding the safety of TNF inhibitors in pregnancy. There have been a few studies looking at infliximab, primarily in the gastroenterology literature. In one report evaluating 58 pregnancies with first trimester exposure, five liveborn infants in the series had complications, two were structurally normal but had complicated neonatal courses and three had structural or developmental complications (one had developmental delay, one had tetralogy of Fallot and one had intestinal malrotation) [35] . Another retrospective evaluation of ten pregnant women with infliximab exposure demonstrated no structural abnormalities; however, three children were born prematurely [36] . Soluble TNF receptors (e.g., etanercept) do cross the placenta in mice but do not appear to impair fetal develop ment [37] . There are a few reports of human data demonstrating embryotoxicity, terato genicity or pregnancy loss. In 14 women who were prescribed etanercept during preg nancy, no malformations were reported [21] . A report from the British Society of Rheumatology Biologics Register (BSRBR) found no structural or developmental abnormalities in 17 pregnan cies and the rate of miscarriage was compar able to that of the general population [38] . The same registry reported no adverse outcomes in three patients who were treated with adalimu mab. Chambers et al. reported on 32 pregnancies from the OTIS registry with TNF exposure, demonstrating no increase in fetal malforma tions, miscarriage or preterm birth [39] . Orozco et al. analyzed 84 pregnancies with TNF expo sure (27% continued through pregnancy). A total of 93% of those studied had live births and most were fullterm. There were two malformations, which is not an increased rate compared with the general population [40] . Carter et al. reported very different findings. The report outlined 41 children with 61 con genital anomalies after TNF inhibitor exposure based on data collected from FDA reports. A total of 56% of the anomalies fell into the ver tebral, anal atresia, cardiac, trachea, esophageal, renal and limb defects (VACTERL) categ ory; the most common anomalies were cardiac and urinary and there were two cases of Down syndrome [41] . Unfortunately, there is no infor mation regarding the total number of patients exposed to TNF antagonists and, thus, the rate of malformations. In other words, we cannot say with certainty if these are related to the drug or are in line with the rate observed in the general population. Furthermore, many individuals in the field of rheumatology have criticized the defini tion of VACTERL used in the Carter paper. Cumulatively, the data appear to indicate that exposure to antiTNF agents in pregnancy does not seem to increase the risks of miscarriage, preterm delivery or congenital malforma tions. However, most available data reflect preconceptional and early first tri mester use in pregnant women with RA or Crohn's dis ease. Current recom mendations for TNF use during pregnancy suggest that conception and early pregnancy are not adversely affected by TNF exposure, and that the potential benefits of continued TNF inhibition during the later stages of pregnancy may outweigh the harm in women with persistent high disease activity [42] .
There are no published data regarding lacta tion and TNF use. There are a few case reports looking at levels of both etanercept and inflix imab in the milk of lactating women, which appear to be very low [43, 44] . However, the effects of these drugs on a young infant are unknown. Theoretically, because these drugs are proteins, they are probably digested in the GI tract and not absorbed in whole systemically. Yet again, physicians should use caution and should coun sel women on this lack of information regarding appropriate use.
Azathioprine
Azathioprine has been used during pregnancy for many years in the management of solid organ transplantation, IBD, malignancy and rheu matic diseases. Azathioprine undergoes hepatic metabo lism to 6mercaptopurine (6MP) and further metabolism to 6thiouric acid (an inac tive metabolite). Azathioprine and its metabo lites (6MP and 6thiouric acid) are known to cross the placenta. In one study, radioactively labeled azathioprine (35Sazathioprine) was administered to humans and the ratio of radio activity in fetal blood compared with mater nal blood was measured. In maternal blood, 27-41% of the administered radio activity was
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present as 6thiouric acid, 14-27% as 6MP and 21-28% as azathioprine. In fetal blood, the majority of radioactivity present (48-63%) was due to thiouric acid (the inactive metabo lite). The majority of radioactivity in amni otic fluid and in the placenta was also due to thiouric acid [45] . Numerous studies of fetal outcomes in pregnant patients treated primar ily for organ trans plantation or IBD have con sistently demon strated a lack of a specific pattern of congenital malformations, although sporadic malformations have been reported [5] . However, most studies confirm an association between azathio prine use and intrauterine growth restric tion and preterm delivery [46] . A recent study of 476 women taking azathioprine during early pregnancy for a variety of indications further supports the increased risk of preterm and low birth weight infants without a statistically signif icant increase in rates or patterns of congenital malformations [47] . It remains unclear whether preterm delivery and lower birth weight are manifestations of the severity of the underlying disease that mandates azathioprine use whether they or are a direct effect of the medication itself. In women with active autoimmune diseases requiring at least moderate immuno suppression, azathio prine remains a good choice and is cer tainly felt to have fewer adverse affects on a pregnancy than methotrexate, mycophenolate mofetil (MMF) or cyclophosphamide.
Use of azathioprine during lactation has been examined in several very small studies [46] . Levels of mercaptopurine in breast milk have been either undetectable or very low in most instances. One study of mercatopurine excreted in the breast milk of eight lactating women on maintenance azathio prine found that the majority of excretion occurs within 4 h of ingestion and that less than 10% of peak maternal milk values are observed by 6 h after ingestion. The authors estimate that exposed infants may ingest mercapto purine at very low levels (<0.008 mg/kg/day) [48] . No adverse events have been reported in breastfed infants who are exposed to maternal azathio prine [46] . Based on these data, it is felt that azathio prine can be taken during lactation without a high risk to the infant.
Mycophenolate mofetil
Mycophenolate mofetil, which is a revers ible inhibitor of inosine monophosphate, was FDA approved in 1995 for use in solid organ transplant ation. It is being used with increasing frequency for the treatment of autoimmune con ditions including lupus nephritis. MMF has been demon strated to be teratogenic in experimental animals, and increasing data from case reports and registry studies support its teratogenicity in humans [49] [50] [51] [52] . MMF readily crosses the placenta. Exposure to MMF during embryogenesis possibly leads to an increased rate of spontaneous abor tions [44] and an estimated 22-26% rate of con genital malformations [49, 50] . A distinctive MMF embryopathy has been identified as the "EMFO tetrad: Ear (microtia and auditory canal atresia); Mouth (cleft lip and palate); Fingers (brachy dactyly fifth fingers and hypoplastic toenails; and Organs (cardiac, renal, CNS, diaphragmatic and ocular)" [49] . Based on these data, the FDA has recently included a Black Box Warning on the package insert discussing terato genicity as a con cern with the use of MMF in women of childbear ing potential [102] . Use of reliable contraception is mandatory for women of childbearing potential. Women taking MMF who wish to become preg nant should discontinue the drug at a minimum of 6 weeks prior to conception. In cases where ongoing immuno suppression is required in order to maintain the mother's health, azathioprine is often considered to be a safer alternative. There are no data regarding the excretion of MMF into breast milk or its effect if it is ingested by infants. Therefore, lactation is also contraindicated while using MMF.
Cyclophosphamide
Cyclophosphamide is an alkylating agent that is commonly used for the treatment of malignan cies, as well as the treatment of lupus nephritis and various forms of vasculitis. Antenatal expo sure to cyclophosphamide early in pregnancy in several animal species and humans is asso ciated with a severe embryopathy that includes cranio synostosis, facial anomalies, distal limb defects and developmental delay [53] . While absolutely contraindicated in the first trimester of pregnancy, cyclophosphamide can be used in the latter half of pregnancy in situations where the life and health of the expectant mother is at risk, most com monly in cases where breast cancer is diagnosed during pregnancy. In one study, three pregnant women diagnosed with breast cancer between weeks 14 and 20 of gestation were reported on; all three women received a combination of cyclo phosphamide and doxorubicin shortly after diagnosis. All three women delivered healthy infants without fetal abnormalities [54] . By con trast, Clowse et al. reported on four lupus patients who were treated with cyclo phosphamide during pregnancy. Two patients who were inadvertently exposed to cyclophosphamide at conception for the treatment of lupus nephritis experienced spontan eous abortions at weeks 9 and 13 of gesta tion. Two additional patients were treated with cyclophosphamide at gestational weeks 20 and 22 for severe multiorgan lupus flareups, and both suffered fetal demise within 7 days of introduction of cyclophosphamide, despite normal ultrasounds prior to treatment [55] . The severity of underlying maternal disease is a likely confounder for these fetal deaths.
Based on these data, cyclophosphamide is contra indicated in early pregnancy and should be used with caution in severely ill women dur ing the second half of pregnancy, although out comes may still be poor for both the mother and fetus. Similarly, lactation is contraindicated dur ing cyclophosphamide use.
Future perspective
It is hard to imagine that randomized con trolled trials of diseasemodifying or immuno suppressive medication use during pregnancy will ever be commonplace. However, as more women achieve adequate control of underlying disease and improved daily function, there are likely to be increasing numbers of women who desire pregnancy and look forward to raising children. The rise of pregnancyrelated registries that incorporate complete data regarding medica tion exposure, coupled with data regarding the severity and activity of underlying disease, will enable a more comprehensive understanding of the risk and benefit analysis of medication use during pregnancy.
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Executive summary
• When counseling women with autoimmune diseases regarding medication use during pregnancy, it is important to balance the potential adverse effects of medication use with the potential adverse effects of untreated, active disease during pregnancy.
• Most data regarding antenatal exposure to disease-modifying or immunosuppressive therapies are based largely on observational data and may be confounded by the severity of the underlying autoimmune disease.
• Hydroxychloroquine can be used safely during pregnancy, and studies have demonstrated an increase in adverse pregnancy outcomes associated with flare-ups of underlying systemic lupus erythematosus in pregnant women who discontinue therapy.
• Methotrexate, leflunomide and mycophenolate mofetil should not be used during pregnancy owing to unacceptable risks of teratogenicity.
• Hydroxychloroquine, corticosteroids, sulfasalazine and azathioprine may be safer alternative agents to control underlying disease during pregnancy.
• Although there does not appear to be a safety signal regarding the use of TNF inhibitors in early pregnancy, few data are available regarding the safety of continued use of TNF inhibitors during the later stages of pregnancy. However, the benefits of better disease control may outweigh the potential risks of ongoing therapy in some cases.
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1. Which of the following is least likely to be a potential adverse effect of nonsteroidal anti-inflammatory drugs (NSAIDs) for pregnancy? 3. A 33-year-old woman with lupus arthritis has a severe exacerbation during the first trimester of pregnancy. Which of the following is safest to use to control her disease during pregnancy?
